Comparison · NCT00936897-sae
Ibandronate 150 mg PO QM vs Denosumab 60 mg SC Q6M: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ibandronate 150 mg PO QM vs Denosumab 60 mg SC Q6M: serious adverse events. Trial comparisons, record NCT00936897-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00936897-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0537 | 0.0357 | 0.0799 | wilson | |
| Risk in group 2 | 0.0949 | 0.0702 | 0.127 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0412 | -0.0781 | -0.00519 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.565 | 0.341 | 0.936 | log | |
| Odds ratio, group 1 over group 2 | 0.541 | 0.315 | 0.93 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Ibandronate 150 mg PO QM than on Denosumab 60 mg SC Q6M | 24.3 | 12.8 | 193 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ibandronate 150 mg PO QM | Ibandronate 150 mg oral monthly | 22 | 410 | EG000 |
| Group 2 | Denosumab 60 mg SC Q6M | Denosumab 60 mg subcutaneous once every 6 months | 39 | 411 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 12 months
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
- NCT number
- NCT00936897
- Phases
- PHASE3
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Ibandronate, Denosumab
- Lead sponsor
- Amgen
- Results first posted
- 2012-11-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00936897?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00936897-sae